Your session is about to expire
← Back to Search
Schwann Cell Therapy for Peripheral Nerve Injury
Study Summary
This trial is studying whether autologous human Schwann cells can improve nerve function in people with severe nerve damage.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a nerve injury with a gap of 5 to 10 cm between ends.I do not have any health conditions that could affect my safety or participation in the study.You have a severe injury to the nerves in your arms or legs that is longer than 10 centimeters.I have had cancer or radiation in the area where I now have nerve damage.You have a history of recent drug or alcohol abuse.You are allergic to gentamicin.You have tested positive for HIV, Hepatitis B, or Hepatitis C.I am between 18 and 65 years old.I have had a severe nerve injury in my arm or leg within the last year.I do not have any major lower limb issues that would affect nerve surgery.I have had a severe nerve injury in my arm or leg within the last year.I have a nerve injury with a gap of 5 to 10 cm between healthy ends.
- Group 1: Autologous human Schwann cells
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the goals of this research endeavor?
"This trial's primary goal is to assess the number of adverse events (AEs) reported over a two-year period post-transplant. Secondary outcomes being evaluated include changes in pain scores as measured by the Douleur Neuropathique 4 questionnaire, alteration in pain characteristics such as location and intensity via a diagramatic representation, along with any variations in muscle strength grade for affected limb muscles assessed using the Medical Research Council scale."
Has the FDA sanctioned autologous human Schwann cells as a viable therapy?
"Due to the limited clinical data associated with autologous human Schwann cells, its safety score was evaluated at 1."
What are the eligibility requirements for participation in this clinical trial?
"This trial seeks 10 individuals, aged 18 to 65 who have had a peripheral nerve injury within the past year and present with 5-10 cm gaps between healthy nerve endings. Qualified candidates must also possess sciatic, brachial plexus or major upper/lower extremity injuries."
Is the upper age limit for participation in this trial above 25 years?
"Conforming to the eligibility requirements of this clinical trial, participants must be at least 18 years old and no more than 65."
Is there capacity within this experiment for additional participants?
"As per the information on clinicaltrials.gov, this study is not currently recruiting patients. The trial was posted on September 24th 2019 and last modified nearly three years later on November 22nd 2022. However, 13 other trials are presently looking for enrollees at present."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger